Darvish Nissim

SEC source: 0001178913-23-002370 · zk2329945.xml · derivative · entry 2

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,572

Underlying: American Depositary Shares · 20,572 shares

Expires 2033-06-14

F1 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F2 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

F3 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-23-001109 · zk2329427.xml · derivative · entry 2

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,857

Underlying: American Depositary Shares · 6,857 shares

Expires 2033-03-21

F2 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F3 · derivative.exercise_date: These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-23-002370 · zk2329945.xml · derivative · entry 3

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,857

Underlying: American Depositary Shares · 6,857 shares

Expires 2033-03-21

F1 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F2 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

F4 · derivative.exercise_date: These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-22-001072 · zk2227476.xml · nonDerivative · entry 1

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,200

F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

F2 · shares: The ADSs are held of record directly by the Ashdanit Medical Ltd. (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole ultimate beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.

SEC source: 0001178913-22-001026 · zk2227457.xml · derivative · entry 1

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,820

Underlying: American Depositary Shares · 6,820 shares

Expires 2032-03-07

F1 · derivative.exercise_date: These options vest and become exercisable in their entirety on March 16, 2023.

F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-22-001072 · zk2227476.xml · derivative · entry 2

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,820

Underlying: American Depositary Shares · 6,820 shares

Expires 2032-03-07

F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F4 · derivative.exercise_date: These options vest and become exercisable in their entirety on March 16, 2023, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-23-001109 · zk2329427.xml · derivative · entry 3

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,820

Underlying: American Depositary Shares · 6,820 shares

Expires 2032-03-07

F2 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F4 · derivative.exercise_date: These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.

F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-23-002370 · zk2329945.xml · derivative · entry 4

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,820

Underlying: American Depositary Shares · 6,820 shares

Expires 2032-03-07

F1 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F2 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

F5 · derivative.exercise_date: These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.

F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001104659-21-053226 · tm2113689-2_4.xml · derivative · entry 1

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,884

Underlying: American Depositary Shares · 11,884 shares

Expires 2031-04-19

F1 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-22-001026 · zk2227457.xml · derivative · entry 2

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,884

Underlying: American Depositary Shares · 11,884 shares

Expires 2031-04-19

F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F4 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-22-001072 · zk2227476.xml · derivative · entry 3

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,884

Underlying: American Depositary Shares · 11,884 shares

Expires 2031-04-19

F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F5 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-23-001109 · zk2329427.xml · derivative · entry 4

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,884

Underlying: American Depositary Shares · 11,884 shares

Expires 2031-04-19

F2 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F5 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-23-002370 · zk2329945.xml · derivative · entry 5

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,884

Underlying: American Depositary Shares · 11,884 shares

Expires 2031-04-19

F1 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F2 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

F6 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-22-001072 · zk2227476.xml · derivative · entry 4

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,123

Underlying: American Depositary Shares · 10,123 shares

Expires 2026-10-27

F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F6 · derivative.exercise_date: The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001551986-20-000294 · wf-form4_160443805938843.xml · nonDerivative · entry 1

Darvish Nissim · CIK 0001793602 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 25,716,755

F1 · kind: The shares of common stock of the Issuer reported on this Form 4 were released from escrow pursuant to Section 1.12 of that certain Agreement and Plan of Merger and Reorganization dated as of October 6, 2019 (as amended by Amendment No. 1 thereto, dated as of December 17, 2019). OrbiMed Israel Partners Limited Partnership's right to receive such escrowed shares became fixed and irrevocable on October 30, 2020, the six-month anniversary of the closing date of the merger.

F2 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. OrbiMed Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001551986-20-000221 · wf-form4_159424015969483.xml · derivative · entry 1

Darvish Nissim · CIK 0001793602 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 100,000

Underlying: Common stock · 100,000 shares

Expires 2030-07-06

F1 · derivative.exercise_date: The option shall vest in 36 equal monthly installments beginning July 6, 2020.

F2 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned indirectly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001551986-20-000205 · wf-form4_159372142840378.xml · derivative · entry 2

Darvish Nissim · CIK 0001793602 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common stock · 6,786,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Convertible Preferred Stock automatically converted to common stock on a 1-to-100 basis upon approval by the Company's stockholders on June 30, 2020.

F2 · derivative.expiration_date: The Series A Convertible Preferred Stock automatically converted to common stock on a 1-to-100 basis upon approval by the Company's stockholders on June 30, 2020.

SEC source: 0001551986-20-000205 · wf-form4_159372142840378.xml · nonDerivative · entry 1

Darvish Nissim · CIK 0001793602 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote 1

Disclosed balance after: 23,773,021

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001551986-20-000136 · wf-form4_158870991773399.xml · derivative · entry 2

Darvish Nissim · CIK 0001793602 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 6,786,500

Underlying: Common stock · 6,786,500 shares

Expires 2025-05-04

F3 · derivative.exercise_price: The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis.

F3 · price: The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis.

SEC source: 0001551986-20-000136 · wf-form4_158870991773399.xml · derivative · entry 1

Darvish Nissim · CIK 0001793602 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 6,786,500

Underlying: Common stock · 6,786,500 shares

Expires not disclosed

F1 · derivative.exercise_price: The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date.

F1 · derivative.expiration_date: The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date.

F2 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001551986-20-000131 · wf-form4_158863562292561.xml · derivative · entry 1

Darvish Nissim · CIK 0001793602 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 50,000

Underlying: Common stock · 50,000 shares

Expires 2030-04-30

F1 · derivative.exercise_date: The option shall vest in 36 equal monthly installments beginning April 30, 2020.

F2 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001178913-23-001109 · zk2329427.xml · derivative · entry 5

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,123

Underlying: American Depositary Shares · 10,123 shares

Expires 2017-10-27

F2 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F6 · derivative.exercise_date: The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.

F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001178913-23-002370 · zk2329945.xml · derivative · entry 6

Darvish Nissim · CIK 0001793602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,123

Underlying: American Depositary Shares · 10,123 shares

Expires 2017-10-27

F1 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

F2 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

F7 · derivative.exercise_date: The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.